Skip to main content

Ampicillin/Sulbactam (Monograph)

Drug class: Aminopenicillins
VA class: AM111
Chemical name: 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, [2S-[2α,5α,6β(S*)]]-6-[(Aminophenylacetyl)amino]-3,3-dimethyl-7-oxo-, mixt. with (2S-cis)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid 4,4-dioxide
CAS number: 94935-63-4

Ampicillin Sodium and Sulbactam Sodium is also contained as an ingredient in the following combinations:
Ampicillin Sodium and Sulbactam Sodium

Medically reviewed by Drugs.com on Jan 23, 2024. Written by ASHP.

Introduction

Antibacterial; β-lactam antibiotic; fixed combination of ampicillin (an aminopenicillin) and sulbactam (a β-lactamase inhibitor).1 27 30 61 64 69

Uses for Ampicillin/Sulbactam

Bone and Joint Infections

Treatment of bone and joint infections† [off-label] (including osteomyelitis and/or septic arthritis) caused by susceptible β-lactamase-producing bacteria.30 58 61 64 90

Intra-abdominal Infections

Treatment of intra-abdominal infections caused by susceptible β-lactamase-producing Escherichia coli, Klebsiella (including K. pneumoniae), Bacteroides (including B. fragilis), or Enterobacter.1 30 47 53 61 64 82 85

Ampicillin and sulbactam (ampicillin/sulbactam) may be as effective as multiple-drug regimens for treatment of less severe intra-abdominal infections, but an aminoglycoside probably should be used concomitantly for empiric therapy in more serious intra-abdominal infections, including hospital-acquired infections, pending results of in vitro susceptibility tests.64 101 102

Gynecologic Infections

Treatment of serious gynecologic infections (e.g., endometritis, postpartum endomyometritis, posthysterectomy pelvic cellulitis, vaginal cuff abscess, salpingitis, tubo-ovarian abscess, pelvic peritonitis or abscess, surgical wound sepsis) caused by susceptible β-lactamase-producing E coli or Bacteroides (including B. fragilis).1 49 50 52 54 55 56 61 74 75 76 83 91

Treatment of pelvic inflammatory disease (PID).344 CDC states that a regimen of IV ampicillin/sulbactam with oral or IV doxycycline is an alternative parenteral regimen for treatment of PID;344 provides good coverage against Chlamydia trachomatis, Neisseria gonorrhoeae, and anaerobes for women with tubo-ovarian abscess.344

Respiratory Tract Infections

Treatment of lower respiratory tract infections† [off-label] (including pneumonia,57 61 77 84 87 89 bronchitis,57 61 84 87 89 acute exacerbations of chronic bronchitis,61 84 87 bronchiectasis)84 87 caused by susceptible Staphylococcus, Streptococcus, Haemophilus influenzae, H. parainfluenzae, Moraxella catarrhalis, E. coli, Klebsiella, or Proteus mirabilis.77 81 84 87 89

ATS and IDSA recommend a regimen of ampicillin/sulbactam with a macrolide (azithromycin or clarithromycin) as one of several options for empiric treatment of nonsevere community-acquired pneumonia (CAP) in hospitalized adults who do not have risk factors for methicillin-resistant S. aureus (MRSA; also known as oxacillin-resistant S. aureus or ORSA) or Pseudomonas aeruginosa.305

Has been used for treatment of respiratory tract infections (e.g., pneumonia, tracheobronchitis) or bacteremia caused by Acinetobacter† [off-label] resistant to imipenem and other anti-infectives.93

Skin and Skin Structure Infections

Treatment of skin and skin structure infections (e.g., wound infections, cellulitis, ulcers, abscesses, furunculosis) caused by susceptible β-lactamase-producing S. aureus,1 58 61 71 87 90 Enterobacter,1 E. coli,1 58 71 87 90 Klebsiella (including K. pneumoniae),1 71 P. mirabilis,1 58 71 90 Bacteroides (including B. fragilis),1 or Acinetobacter.1 30 48 58 61 64 86 87 90

Also has been used for treatment of skin and skin structure infections caused by susceptible S. epidermidis† [off-label],58 71 87 90 S. warneri† [off-label],58 90 Enterococcus faecalis†,58 71 90 Citrobacter†,71 or Morganella morganii†.58 90

Bite Wounds

Empiric treatment of animal or human bites†.5 Active against most likely bite pathogens, including anaerobes, Staphylococcus, Eikenella corrodens, Pasteurella multocida.5

Alternative for treatment of infections caused by P. multocida† or E. corrodens†.4 5

Endocarditis

Treatment of endocarditis†.61

Although other regimens preferred, AHA states a regimen of ampicillin/sulbactam and an aminoglycoside can be considered as an alternative for treatment of endocarditis involving native valves or prosthetic valves or other prosthetic material caused by β-lactamase-producing Enterococcus.450 AHA also states ampicillin/sulbactam may be considered an option for treatment of endocarditis cause by fastidious gram-negative bacilli of the HACEK group (i.e., Haemophilus, Aggregatibacter, Cardiobacterium hominis, Eikenella corrodens, Kingella).450 452

Consult current guidelines from AHA for information on management of endocarditis.450 452

Gonorrhea and Associated Infections

Has been used for treatment of uncomplicated gonorrhea† caused by susceptible penicillinase-producing strains of N. gonorrhoeae (PPNG) and nonpenicillinase-producing strains.30 47 61 80 94 95 However, CDC has not recommended use of penicillins for treatment of gonococcal infections for over 30 years because of the widespread prevalence of PPNG.265 344

Meningitis

Alternative for treatment of meningitis† caused by susceptible H. influenzae, N. meningitidis, or S. pneumoniae.78 59 61 87 Other drugs generally preferred;61 101 treatment failures reported when used for treatment of meningitis caused by K. pneumoniae.35

Perioperative Prophylaxis

Perioperative prophylaxis† to reduce the incidence of infections in patients undergoing certain contaminated or potentially contaminated surgery (e.g., GI or biliary tract surgery, vaginal or abdominal hysterectomy).30 51 60 61 96 97 98 99

Ampicillin/sulbactam is one of several options recommended for perioperative prophylaxis in patients undergoing biliary tact surgery, colorectal surgery, gynecologic and obstetric procedures (e.g., vaginal, abdominal, or laparoscopic hysterectomy), head and neck surgery (involving incisions through oral or pharyngeal mucosa), non-cardiac thoracic surgery (e.g., lobectomy, pneumonectomy, lung resection, thoracotomy), or urologic procedures involving implanted prosthesis.96 97

Consider local susceptibility patterns of potential pathogens when considering ampicillin/sulbactam for perioperative prophylaxis in procedures that involve exposure to bowel flora (e.g., E. coli) that may be resistant to the drug.96 97

Ampicillin/Sulbactam Dosage and Administration

Administration

Administer by slow IV injection or IV infusion or by IM injection.1

Dosage is the same for IM and IV administration;1 higher serum concentrations usually are attained with IV administration1 30 33 46 63 67 and IV route generally preferred, especially for severe infections.101 102

For solution and drug compatibility information, see Compatibility under Stability.

IV Administration

Reconstitution and Dilution

IV solutions are prepared by reconstituting vials containing 1.5 or 3 g of ampicillin/sulbactam with sterile water for injection to provide solutions containing 375 mg/mL (250 mg of ampicillin and 125 mg of sulbactam per mL).1 An appropriate volume of the reconstituted solution should then be immediately diluted with a compatible IV solution to yield solutions containing 3–45 mg/mL (2–30 mg of ampicillin and 1–15 mg of sulbactam per mL).1

IV solutions should be allowed to stand after dissolution to allow any foaming to dissipate in order to permit visual inspection for complete solubilization.1

Rate of Administration

IV injection: Administer slowly over a period of ≥10–15 minutes.1

IV infusion: Administer over 15–30 minutes.1

IM Administration

IM injections should be made deeply into a large muscle mass.1

Reconstitution

IM solutions are prepared by reconstituting vials containing 1.5 or 3 g of ampicillin/sulbactam with 3.2 or 6.4 mL, respectively, of sterile water for injection or 0.5 or 2% lidocaine hydrochloride injection to provide a solution containing 375 mg of the drug per mL (250 mg of ampicillin and 125 mg of sulbactam per mL).1 Use of lidocaine hydrochloride can minimize local pain associated with IM injection of the drug.47 64 92

IM solutions should be allowed to stand after dissolution to allow any foaming to dissipate in order to permit visual inspection for complete solubilization.1

Use IM solutions within 1 hour after reconstitution.1

Dosage

Available as fixed combination ampicillin/sulbactam containing a 2:1 ratio of ampicillin to sulbactam.1

Ampicillin component provided as ampicillin sodium and sulbactam component provided as sulbactam sodium; potency of each is expressed in terms of the base.1

Dosage of ampicillin/sulbactam usually is expressed in terms of the total (sum) of the dosage of both components of the fixed combination (i.e., dosage of ampicillin plus dosage of sulbactam);1 pediatric dosage of ampicillin/sulbactam also has been expressed in terms of the ampicillin content.5

Pediatric Patients

General Pediatric Dosage
IV

Manufacturer states pediatric patients weighing ≥40 kg may receive the usual adult dosage.1

Pediatric patients beyond the neonatal period†: AAP recommends 100–200 mg/kg of ampicillin daily (as ampicillin/sulbactam) in 4 divided doses.5 A dosage of 200–400 mg/kg of ampicillin daily (as ampicillin/sulbactam) in 4 divided doses recommended for meningitis† or severe infections caused by resistant S. pneumoniae.5

Skin and Skin Structure Infections
IV

Children ≥1 year of age: 300 mg/kg daily (200 mg of ampicillin and 100 mg of sulbactam) in equally divided doses every 6 hours.1

Manufacturer states IV treatment in pediatric patients should not exceed 14 days; in clinical studies, most children received an appropriate oral anti-infective after an initial regimen of IV ampicillin/sulbactam.1

Pelvic Inflammatory Disease
IV

Adolescents: 3 g (2 g of ampicillin and 1 g of sulbactam) every 6 hours in conjunction with doxycycline (100 mg orally or IV every 12 hours).344 Parenteral regimen may be discontinued 24–48 hours after clinical improvement; switch to oral regimen of doxycycline (100 mg twice daily) and metronidazole (500 mg twice daily) to complete 14 days of therapy.344

Perioperative Prophylaxis†
IV

50 mg/kg of ampicillin (as ampicillin/sulbactam) within 60 minutes prior to initial incision.97

May give additional intraoperative doses every 2 hours during prolonged procedures;96 97 postoperative doses generally not recommended.96 97

Adults

Intra-abdominal, Gynecologic, or Skin and Skin Structure Infections
IV or IM

1.5 g (1 g of ampicillin and 0.5 g of sulbactam) to 3 g (2 g of ampicillin and 1 g of sulbactam) every 6 hours.1

Pelvic Inflammatory Disease
IV

3 g (2 g of ampicillin and 1 g of sulbactam) every 6 hours in conjunction with doxycycline (100 mg orally or IV every 12 hours).344 Parenteral regimen may be discontinued 24–48 hours after clinical improvement; switch to oral regimen of doxycycline (100 mg twice daily) and metronidazole (500 mg twice daily) to complete 14 days of therapy.344

Respiratory Tract Infections†
IV

Empiric treatment of nonsevere CAP in hospitalized adults without risk factors for MRSA or Ps. aeruginosa: ATS and IDSA recommend 1.5 g (1 of ampicillin and 0.5 g of sulbactam) to 3 g (2 g of ampicillin and 1 g of sulbactam) every 6 hours in conjunction with azithromycin (500 mg daily) or clarithromycin (500 mg twice daily).305

Endocarditis†
IV

Treatment of endocarditis cause by β-lactamase-producing Enterococcus: AHA recommends 3 g (2 g of ampicillin and 1 g of sulbactam) every 6 hours given in conjunction with an aminoglycoside.450

Perioperative Prophylaxis†
IV

3 g (2 g of ampicillin and 1 g of sulbactam) given within 60 minutes prior to initial incision.96 97

May give additional intraoperative doses every 2 hours during prolonged procedures;96 97 postoperative doses generally not recommended.96 97

Prescribing Limits

Pediatric Patients

IV

Maximum sulbactam dosage is 4 g (i.e., 8 g of ampicillin and 4 g of sulbactam in fixed combination) daily.1

Duration of therapy should be ≤14 days.1

Adults

IV or IM

Maximum sulbactam dosage is 4 g (i.e., 8 g of ampicillin and 4 g of sulbactam in fixed combination) daily.1

Special Populations

Renal Impairment

Dosage adjustments necessary in patients with renal impairment.1 61

Patients with renal impairment should receive the usually recommended dose but these doses should be given less frequently than usual; dosing intervals are based on the patient’s Clcr.1 The manufacturer recommends that patients with Clcr ≥30 mL/minute per 1.73 m2 should receive 1.5 g (1 g of ampicillin and 0.5 g of sulbactam) to 3 g (2 g of ampicillin and 1 g of sulbactam) every 6–8 hours and patients with Clcr 15–29 or 5–14 mL/minute per 1.73 m2 should receive these doses every 12 or 24 hours, respectively.1

Some clinicians suggest that patients undergoing hemodialysis receive 1.5 g (1 g of ampicillin and 0.5 g of sulbactam) to 3 g (2 g of ampicillin and 1 g of sulbactam) once every 24 hours and that the dose should preferably be given immediately after dialysis.34 72

Geriatric Patients

No dosage adjustments except those related to renal impairment. (See Renal Impairment under Dosage and Administration.)

Detailed Ampicillin / sulbactam dosage information

Cautions for Ampicillin/Sulbactam

Contraindications

Warnings/Precautions

Warnings

Superinfection/Clostridioides difficile-associated Colitis

Possible emergence and overgrowth of nonsusceptible bacteria or fungi (e.g., Pseudomonas, Candida).1 Discontinue and institute appropriate therapy if superinfection occurs.1

Treatment with anti-infectives alters normal colon flora and may permit overgrowth of C. difficile.1 302 C. difficile infection (CDI) and C. difficile-associated diarrhea and colitis (CDAD; also known as antibiotic-associated diarrhea and colitis or pseudomembranous colitis) reported with nearly all anti-infectives, including ampicillin/sulbactam, and may range in severity from mild diarrhea to fatal colitis.1 302 C. difficile produces toxins A and B which contribute to development of CDAD;1 302 hypertoxin-producing strains of C. difficile are associated with increased morbidity and mortality since they may be refractory to anti-infectives and colectomy may be required.1

Consider CDAD if diarrhea develops during or after therapy and manage accordingly.1 302 Obtain careful medical history since CDAD may occur as late as ≥2 months after anti-infective therapy is discontinued.1

If CDAD suspected or confirmed, discontinue anti-infectives not directed against C. difficile as soon as possible.1 302 Initiate appropriate anti-infective therapy directed against C. difficile (e.g., fidaxomicin, vancomycin, metronidazole), appropriate supportive therapy (e.g., fluid and electrolyte management, protein supplementation), and surgical evaluation as clinically indicated.302

Hepatotoxicity

Has been associated with hepatic dysfunction, including hepatitis and cholestatic jaundice.1 Although hepatotoxicity usually reversible, deaths reported.1

If used in patients with hepatic impairment, monitor hepatic function at regular intervals.1

Severe Cutaneous Reactions

May cause severe skin reactions, such as toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome (SJS), dermatitis exfoliative, erythema multiforme, and acute generalized exanthematous pustulosis (AGEP).1

If patient develops a rash, monitor closely and discontinue ampicillin/sulbactam if lesions progress.1

Sensitivity Reactions

Hypersensitivity Reactions

Serious and occasionally fatal hypersensitivity reactions, including anaphylaxis, reported with penicillins.1 These reactions may occur in individuals with a history of penicillin hypersensitivity and/or hypersensitivity reactions to multiple allergens.1 There have been reports of individuals with a history of penicillin hypersensitivity who have experienced severe reactions when treated with cephalosporins.1

Prior to initiation of ampicillin/sulbactam, make careful inquiry regarding previous hypersensitivity reactions to penicillins, cephalosporins, or other allergens.1

If an allergic reaction occurs, immediately discontinue ampicillin/sulbactam and institute appropriate therapy as indicated.1

General Precautions

Selection and Use of Anti-infectives

To reduce development of drug-resistant bacteria and maintain effectiveness of ampicillin/sulbactam and other antibacterials, use only for treatment or prevention of infections proven or strongly suspected to be caused by susceptible bacteria.1 Prescribing the drug in the absence of proven or strongly suspected bacterial infection unlikely to provide benefit to the patient and increases risk of development of drug-resistant bacteria.1

When selecting or modifying anti-infective therapy, use results of culture and in vitro susceptibility testing.1 In the absence of such data, consider local epidemiology and susceptibility patterns when selecting anti-infectives for empiric therapy.1

Information on test methods and quality control standards for in vitro susceptibility testing of antibacterials and specific interpretive criteria for such testing recognized by FDA is available at [Web].1 303 For most antibacterials, including ampicillin/sulbactam, FDA recognizes the standards published by the Clinical and Laboratory Standards Institute (CLSI).303 304

Mononucleosis

A high percentage of patients with mononucleosis who receive ampicillin develop a skin rash.1

Do not use ampicillin in patients with mononucleosis.1

Use of Fixed Combination

Consider cautions, precautions, contraindications, and drug interactions associated with both drugs in the fixed combination.

When prescribing, preparing, and dispensing ampicillin/sulbactam, consider that dosage of the fixed combination usually is expressed as the total (sum) of the dosage of each of the 2 components in the fixed combination (i.e., dosage of ampicillin plus dosage of sulbactam).1

Sodium Content

Each 1.5 g (1 g of ampicillin and 0.5 g of sulbactam) contains approximately 5 mEq (115 mg) of sodium.1

Specific Populations

Pregnancy

There are no adequate and well-controlled studies using ampicillin/sulbactam in pregnant women.1 Reproduction studies in mice, rats, and rabbits at doses up to 10 times the human dose have not revealed evidence of impaired fertility or harm to the fetus due to ampicillin and sulbactam.1 Because animal reproduction studies are not always predictive of human response, use during pregnancy only if clearly needed.1

Although clinical importance unclear, administration of ampicillin alone to pregnant women has resulted in transient decreases in plasma concentrations of total conjugated estriol, estriol glucuronide, conjugated estrone, and estradiol; this effect also may occur following administration of ampicillin/sulbactam.1 In studies in guinea pigs, IV ampicillin decreased uterine tone, frequency of contractions, height of contractions, and duration of contractions. 1 However, it is not known whether use of ampicillin/sulbactam in humans during labor or delivery could have any immediate or delayed adverse effects on the fetus, prolong the duration of labor, or increase the likelihood that forceps delivery or other obstetrical intervention or resuscitation of the newborn will be necessary.1

Lactation

Both ampicillin and sulbactam are distributed into milk in low concentrations.1

Use with caution in nursing women.1

Pediatric Use

Safety and efficacy of IV ampicillin/sulbactam established for treatment of skin and skin structure infections in children ≥1 year of age, but not established for treatment of intra-abdominal infections or any other indications in this age group.1

Safety and efficacy of IM ampicillin/sulbactam not established for any indication in pediatric patients.1

Adverse effects reported in pediatric patients similar to those reported in adults.1

Geriatric Use

Serum half-lives of ampicillin and sulbactam slightly longer in geriatric adults than in younger adults;31 61 not considered clinically important in geriatric patients with renal function normal for their age.66

No dosage adjustments except those related to renal function.1

Renal Impairment

Dosage adjustments necessary in renal impairment.1 (See Renal Impairment under Dosage and Administration.)

Common Adverse Effects

Local reactions (pain at IM or IV injection sites, thrombophlebitis, phlebitis);1 30 57 77 80 87 GI effects (diarrhea, nausea, vomiting),1 30 rash.1

Drug Interactions

Specific Drugs and Laboratory Tests

Drug or Test

Interaction

Comments

Allopurinol

Concomitant use with ampicillin substantially increases incidence of rash reported with ampicillin;1 14 19 data not available regarding concomitant use with ampicillin/sulbactam 1

Unclear whether potentiation of rash is caused by allopurinol or hyperuricemia present in these patients1

Aminoglycosides

In vitro evidence of synergistic antibacterial effects against enterococci;11 116 282 used to therapeutic advantage in treatment of endocarditis and other severe enterococcal infections10 282 450

Potential in vitro and in vivo inactivation of aminoglycosides1 61 70

Methotrexate

Penicillins may decrease renal clearance of methotrexate; possible increased methotrexate concentrations and hematologic and GI toxicity109

Monitor closely if used concomitantly109

Probenecid

Decreased renal tubular secretion of ampicillin and sulbactam; increased and prolonged ampicillin and sulbactam concentrations may occur1 30 33 61 65

Tests for glucose

Possible false-positive reactions in urine glucose tests using Clinitest, Benedict’s solution, or Fehling’s solution1

Use glucose tests based on enzymatic glucose oxidase reactions (e.g., Clinistix, Tes-Tape)1

Tests for uric acid

Possible falsely increased serum uric acid concentrations when copper-chelate method is used;20 phosphotungstate and uricase methods appear to be unaffected by ampicillin20
Ampicillin / sulbactam drug interactions (more detail)

Ampicillin/Sulbactam Pharmacokinetics

Absorption

Bioavailability

Peak ampicillin serum concentrations attained with ampicillin/sulbactam are similar to those attained with ampicillin alone.1

Peak serum concentrations of ampicillin and sulbactam are attained immediately following completion of a 15-minute IV infusion of ampicillin/sulbactam.1 63

Following IM injection of ampicillin/sulbactam, both drugs are rapidly and almost completely absorbed;30 33 46 67 peak serum concentrations of ampicillin and sulbactam generally attained within 30–40 and 30–52 minutes, respectively.30 67

Peak serum concentrations and AUCs of ampicillin and sulbactam are slightly higher in geriatric patients than in younger adults, presumably because of reduced renal clearance in the elderly.31 61

Distribution

Extent

Both ampicillin and sulbactam widely are distributed into fluids and tissues,1 30 33 61 including peritoneal fluid,1 30 43 44 60 61 65 blister fluid,1 30 36 61 65 68 tissue fluid,1 sputum,30 61 middle ear effusion,61 65 intestinal mucosa,1 30 45 65 bronchial wall,42 alveolar lining fluid,42 sternum,41 pericardium,41 myocardium,41 endocardium,41 prostate,30 65 gallbladder,30 39 65 bile,30 39 65 myometrium,30 65 73 salpinges,30 65 73 ovaries,30 65 73 and appendix.1 60 65 Concentrations of the drugs in most of these tissues and fluids are 53–100% of concurrent serum concentrations.33 42 43 65

Both ampicillin and sulbactam are distributed into CSF in low concentrations following IV or IM administration.1 30 35 37 38 59 61 65 CSF concentrations generally higher in patients with inflamed meninges than in those with uninflamed meninges.35 37 38 59 65

Ampicillin and sulbactam both readily cross the placenta30 61 65 and concentrations in umbilical cord blood may be similar to serum concentrations.65 Ampicillin and sulbactam both distributed into milk in low concentrations.1 30 65 108

Plasma Protein Binding

Ampicillin approximately 15–28% and sulbactam approximately 38% bound to serum proteins.1 33 61 65

Elimination

Metabolism

Both ampicillin and sulbactam partially metabolized in the liver.61 Ampicillin partially metabolized by hydrolysis of the β-lactam ring to penicilloic acid which is microbiologically inactive.61

Elimination Route

Both ampicillin and sulbactam eliminated in urine principally by glomerular filtration and tubular secretion.30 33 34 46 61 65 Only small amounts of the drugs eliminated in feces and bile.33 45 61

Following IM or IV administration of ampicillin/sulbactam in adults with normal renal function, approximately 75–92% of the dose of both ampicillin and sulbactam excreted unchanged in urine within 8 hours.1 65 67

Ampicillin and sulbactam both removed by hemodialysis.1 34

Half-life

In healthy adults with normal renal function, both ampicillin and sulbactam have a distribution half-life of about 15 minutes and an elimination half-life of about 1 hour.1 33 65 67

In infants and children <12 years of age, sulbactam has an elimination half-life of 0.92–1.9 hours.32 33 In neonates, half-lives of ampicillin and sulbactam vary inversely with age; as renal tubular function matures, the drugs are cleared more rapidly.33 40 65 66 In premature neonates ≤6 days of age, half-life of ampicillin averages 9.4 hours and half-life of sulbactam averages 7.9 hours.29

Special Populations

Half-lives are slightly longer in geriatric adults than in younger adults29 31 61 (2.2 hours compared with 0.8–1.2 hours in younger adults).29

Serum concentrations of both ampicillin and sulbactam are higher and half-lives prolonged in patients with renal impairment.1 29 30 33 34 61 65 Half-lives of ampicillin and sulbactam average 1.6 and 1.6 hours, respectively, in adults with Clcr 30–60 mL/minute and average 3.4 and 3.7 hours, respectively, in those with Clcr 7–30 mL/minute.34 In adults with Clcr <7 mL/minute, elimination half-life of ampicillin and sulbactam average 17.4 and 13.4 hours, respectively.34

Cystic fibrosis patients may eliminate sulbactam at faster rates than healthy individuals.29 32 65

Stability

Storage

Parenteral

Powder for Injection or Infusion

20–25°C.1

IV solutions containing 45 mg/mL (30 mg of ampicillin and 15 mg of sulbactam per mL) prepared using sterile water for injection or 0.9% sodium chloride injection are stable for 8 hours at 25°C or 48 hours at 4°C;1 solutions containing 30 mg/mL (20 mg of ampicillin and 10 mg of sulbactam per mL) are stable for 72 hours at 4°C.1

IV solutions containing 45 mg/mL (30 mg of ampicillin and 15 mg of sulbactam per mL) in lactated Ringer’s injection or (1/6) M sodium lactate injection are stable for 8 hours at 25°C or for 24 or 8 hours, respectively, when refrigerated at 4°C.1

IV solutions containing 30 mg/mL (20 mg of ampicillin and 10 mg of sulbactam per mL) in 5% dextrose injection are stable for 2 hours at 25°C or 4 hours when refrigerated at 4°C; those containing 3 mg/mL (2 mg of ampicillin and 1 mg of sulbactam per mL) are stable for 4 hours at 25°C.1

IM solutions containing 375 mg/mL (250 mg of ampicillin and 125 mg of sulbactam per mL) prepared using sterile water for injection or 0.5 or 2% lidocaine hydrochloride injection should be administered within 1 hour after reconstitution.1

Compatibility

Parenteral

Solution Compatibility301

Compatible

Sodium chloride 0.9%
Drug Compatibility
Admixture Compatibility301

Compatible

Aztreonam

Tramadol HCl

Incompatible

Ciprofloxacin
Y-site Compatibility301

Compatible

Amifostine

Anidulafungin

Aztreonam

Bivalirudin

Cangrelor tetrasodium

Ceftolozane sulfate-tazobactam sodium

Dexmedetomidine HCl

Docetaxel

Enalaprilat

Etoposide phosphate

Famotidine

Fenoldopam mesylate

Filgrastim

Fluconazole

Fludarabine phosphate

Gallium nitrate

Gemcitabine HCl

Granisetron HCl

Heparin sodium

Hetastarch in lactated electrolyte injection (Hextend)

Imipenem-cilastatin sodium-relebactam

Insulin, regular

Letermovir

Linezolid

Meperidine HCl

Meropenem-vaborbactam

Morphine sulfate

Paclitaxel

Palonosetron HCl

Pemetrexed sodium

Plazomicin sulfate

Remifentanil HCl

Tacrolimus

Telavancin HCl

Teniposide

Theophylline

Thiotepa

Incompatible

Amiodarone HCl

Ciprofloxacin

Idarubicin HCl

Nicardipine HCl

Ondansetron HCl

Sargramostim

Variable

Cisatracurium besylate

Diltiazem HCl

Vancomycin HCl

Actions and Spectrum

Advice to Patients

Preparations

Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.

* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name

Ampicillin Sodium and Sulbactam Sodium

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Parenteral

For injection

1 g (of ampicillin) and 0.5 g (of sulbactam) (labeled as a combined total potency of 1.5 g)*

Ampicillin and Sulbactam for Injection

Unasyn

Pfizer

2 g (of ampicillin) and 1 g (of sulbactam) (labeled as a combined total potency of 3 g)*

Ampicillin and Sulbactam for Injection

Unasyn

Pfizer

10 g (of ampicillin) and 5 g (of sulbactam) (labeled as a combined total potency of 15 g) pharmacy bulk package*

Ampicillin and Sulbactam for Injection

Unasyn

Pfizer

AHFS DI Essentials™. © Copyright 2024, Selected Revisions February 2, 2022. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.

† Off-label: Use is not currently included in the labeling approved by the US Food and Drug Administration.

References

1. Mylan. Ampicillin sodium and sulbactam sodium for injection prescribing information. Morgantown, WV; 2020 Dec.

4. Anon. The choice of antibacterial drugs. Med Lett Drugs Ther. 2001; 43:69-78. http://www.ncbi.nlm.nih.gov/pubmed/11518876?dopt=AbstractPlus

5. American Academy of Pediatrics. Red Book: 2018–2021 Report of the Committee on Infectious Diseases. 31st ed. Itasca, IL: American Academy of Pediatrics.

10. Bennett JE, Dolin R, Blaser MK, eds. Mandell, Douglas, and Bennett’s principles and practice of infectious diseases. 8th ed. Elsevier Saunders; Philadelphia, PA; 2015.

11. Iannini PB, Ehret J, Eickhoff TC. Effects of ampicillin-amikacin and ampicillin-rifampin on enterococci. Antimicrob Agents Chemother. 1976; 9:448-51. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=429550&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/1045914?dopt=AbstractPlus

14. Murphy TF. Ampicillin rash and hyperuricemia. Ann Intern Med. 1979; 91:324. http://www.ncbi.nlm.nih.gov/pubmed/157097?dopt=AbstractPlus

19. Jick H, Porter JB. Potentiation of ampicillin skin reactions by allopurinol or hyperuricemia. J Clin Pharmacol. 1981; 21:456-8. http://www.ncbi.nlm.nih.gov/pubmed/6458626?dopt=AbstractPlus

20. Lum G, Gambino SR. Comparison of four methods for measuring uric acid: copper-chelate, phosphotungstate, manual uricase, and automated kinetic uricase. Clin Chem. 1973; 19:1184-6. http://www.ncbi.nlm.nih.gov/pubmed/4741958?dopt=AbstractPlus

27. Drawz SM, Bonomo RA. Three decades of beta-lactamase inhibitors. Clin Microbiol Rev. 2010; 23:160-201. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=2806661&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/20065329?dopt=AbstractPlus

29. Benson JM, Nahata MC. Sulbactam/ampicillin, a new beta-lactamase inhibitor/beta-lactam antibiotic combination. DICP. 1988; 22:534-41.

30. Campoli-Richards DM, Brogden RN. Sulbactam/ampicillin: a review of its antibacterial activity, pharmacokinetic properties, and therapeutic use. Drugs. 1987; 33:577-609. http://www.ncbi.nlm.nih.gov/pubmed/3038500?dopt=AbstractPlus

31. Meyers BR, Wilkinson P, Mendelson MH et al. Pharmacokinetics of ampicillin-sulbactam in healthy elderly and young volunteers. Antimicrob Agents Chemother. 1991; 35:2098-101. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=245332&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/1759832?dopt=AbstractPlus

32. Schaad UB, Guenin K, Straehl P. Single-dose pharmacokinetics of intravenous sulbactam in pediatric patients. Rev Infect Dis. 1986; 8(Suppl 5):S512-6. http://www.ncbi.nlm.nih.gov/pubmed/3025998?dopt=AbstractPlus

33. Foulds G. Pharmacokinetics of sulbactam/ampicillin in humans: a review. Rev Infect Dis. 1986; 8(Suppl 5):S503-10. http://www.ncbi.nlm.nih.gov/pubmed/3025997?dopt=AbstractPlus

34. Blum RA, Kohli RK, Harrison NJ et al. Pharmacokinetics of ampicillin (2.0 grams) and sulbactam (1.0 gram) coadministered to subjects with normal and abnormal renal function and with end-stage renal disease on hemodialysis. Antimicrob Agents Chemother. 1989; 33:1470-6. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=172685&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/2817847?dopt=AbstractPlus

35. Foulds G, McBride TJ, Knirsch AK et al. Penetration of sulbactam and ampicillin into cerebrospinal fluid of infants and young children with meningitis. Antimicrob Agents Chemother. 1987; 31:1703-5. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=175024&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/3435118?dopt=AbstractPlus

36. Brown RM, Wise R, Andrews JM et al. Comparative pharmacokinetics and tissue penetration of sulbactam and ampicillin after concurrent intravenous administration. Antimicrob Agents Chemother. 1982; 21:565-7. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=181942&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/6282211?dopt=AbstractPlus

37. Stahl JP, Bru JP, Fredj G et al. Penetration of sulbactam into the cerebrospinal fluid of patients with bacterial meningitis receiving ampicillin therapy. Rev Infect Dis. 1986; 8(Suppl 5):S612-6. http://www.ncbi.nlm.nih.gov/pubmed/3026013?dopt=AbstractPlus

38. Hänninen P, Rossi T. Penetration of sulbactam into cerebrospinal fluid of patients with viral meningitis or without meningitis. Rev Infect Dis. 1986; 8(Suppl 5):S609-11. http://www.ncbi.nlm.nih.gov/pubmed/3026012?dopt=AbstractPlus

39. Morris DL, Ubhi CS, Roberson CS et al. Biliary pharmacokinetics of sulbactam plus ampicillin in humans. Rev Infect Dis. 1986; 8(Suppl 5):S589-92.

40. Sutton AM, Turner TL, Cockburn F et al. Pharmacokinetic study of sulbactam and ampicillin administered concomitantly by intraarterial or intravenous infusion in the newborn. Rev Infect Dis. 1986; 8(Suppl 5):S518-22. http://www.ncbi.nlm.nih.gov/pubmed/3025999?dopt=AbstractPlus

41. Wildfeuer A, Müller V, Springsklee M et al. Pharmacokinetics of ampicillin and sulbactam in patients undergoing heart surgery. Antimicrob Agents Chemother. 1991; 35:1772-6. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=245266&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/1952846?dopt=AbstractPlus

42. Valcke YJ, Rosseel MT, Pauwels RA et al. Penetration of ampicillin and sulbactam in the lower airways during respiratory infections. Antimicrob Agents Chemother. 1990; 34:958-62. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=171737&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/2393293?dopt=AbstractPlus

43. Wise R, Donovan IA, Andrews JM et al. Penetration of sulbactam and ampicillin into peritoneal fluid. Antimicrob Agents Chemother. 1983; 24:290-2. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=185155&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/6314889?dopt=AbstractPlus

44. Houang ET, Colley N, Chapman M. Penetration of sulbactam-ampicillin and clavulanic acid-amoxicillin into the pelvic peritoneum. Antimicrob Agents Chemother. 1985; 28:165-6. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=176335&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/2994556?dopt=AbstractPlus

45. Kager L, Liljeqvist L, Malmborg AS et al. Effects of ampicillin plus sulbactam on bowel flora in patients undergoing colorectal surgery. Antimicrob Agents Chemother. 1982; 22:208-12. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=183712&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/6100422?dopt=AbstractPlus

46. Foulds G, Stankewich JP, Marshall DC et al. Pharmacokinetics of sulbactam in humans. Antimicrob Agents Chemother. 1983; 23:692-9. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=184789&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/6307133?dopt=AbstractPlus

47. Lees L, Milson JA, Knirsch AK et al. Sulbactam plus ampicillin: interim review of efficacy and safety for therapeutic and prophylactic use. Rev Infect Dis. 1986; 8(Suppl 5):S644-50. http://www.ncbi.nlm.nih.gov/pubmed/3026019?dopt=AbstractPlus

48. Stromberg BV, Reines HD, Hunt P. Comparative clinical study of sulbactam and ampicillin and clindamycin and tobramycin in infections of soft tissues. Surg Gynecol Obstet. 1986; 162:575-8. http://www.ncbi.nlm.nih.gov/pubmed/3012808?dopt=AbstractPlus

49. Senft HH, Stiglmayer R, Eibach HW et al. Sulbactam/ampicillin versus cefoxitin in the treatment of obstetric and gynaecological infections. Drugs. 1986; 31(Suppl 2):18-21. http://www.ncbi.nlm.nih.gov/pubmed/3013568?dopt=AbstractPlus

50. Hemsell DL. Sulbactam/ampicillin for treatment of polymicrobial pelvic infections. Drugs. 1986; 31(Suppl 2):22-5. http://www.ncbi.nlm.nih.gov/pubmed/3013569?dopt=AbstractPlus

51. Krohn KT. Effect of prophylactic administration of sulbactam/ampicillin on the rate of postoperative endometritis after first-trimester abortion. Rev Infect Dis. 1986; 8(Suppl 5):S576-8. http://www.ncbi.nlm.nih.gov/pubmed/3026006?dopt=AbstractPlus

52. Giamarellou H, Trouvas G, Avlami A et al. Efficacy of sulbactam plus ampicillin in gynecologic infections. Rev Infect Dis. 1986; 8(Suppl 5):S579-82. http://www.ncbi.nlm.nih.gov/pubmed/3026007?dopt=AbstractPlus

53. Study Group of Intraabdominal Infections. A randomized controlled trial of ampicillin plus sulbactam vs. gentamicin plus clindamycin in the treatment of intraabdominal infections: a preliminary report. Rev Infect Dis. 1986; 8(Suppl 5):S583-8.

54. Martens MG, Faro S, Hammill HA et al. Ampicillin/sulbactam versus clindamycin in the treatment of postpartum endomyometritis. South Med J. 1990; 83:408-13. http://www.ncbi.nlm.nih.gov/pubmed/2181689?dopt=AbstractPlus

55. Crombleholme WR, Ohm-Smith M, Robbie MO et al. Ampicillin/sulbactam versus metronidazole-gentamicin in the treatment of soft tissue pelvic infections. Am J Obstet Gynecol. 1987; 156:507-12. http://www.ncbi.nlm.nih.gov/pubmed/3030109?dopt=AbstractPlus

56. Reed SD, Landers DV, Sweet RL. Antibiotic treatment of tuboovarian abscess: comparison of broad-spectrum β-lactam agents versus clindamycin-containing regimens. Am J Obstet Gynecol. 1991; 164:1556-62. http://www.ncbi.nlm.nih.gov/pubmed/2048603?dopt=AbstractPlus

57. Mehtar S, Croft RJ, Hilas A. A non-comparative study of parenteral ampicillin and sulbactam in intra-thoracic and intra-abdominal infections. J Antimicrob Chemother. 1986; 17:389-96. http://www.ncbi.nlm.nih.gov/pubmed/3009384?dopt=AbstractPlus

58. Löffler L, Bauernfeind A, Keyl W et al. An open, comparative study of sulbactam plus ampicillin vs. cefotaxime as initial therapy for serious soft tissue and bone and joint infections. Rev Infect Dis. 1986; 8(Suppl 5):S593-8. http://www.ncbi.nlm.nih.gov/pubmed/3026009?dopt=AbstractPlus

59. Rodrgúez WJ, Khan WN, Puig J et al. Sulbactam/ampicillin vs. chloramphenicol/ampicillin for the treatment of meningitis in infants and children. Rev Infect Dis. 1986; 8(Suppl 5):S620-9. http://www.ncbi.nlm.nih.gov/pubmed/3026015?dopt=AbstractPlus

60. Foster MC, Kapila L, Morris DL et al. A randomized comparative study of sulbactam plus ampicillin vs. metronidazole plus cefotaxime in the management of acute appendicitis in children. Rev Infect Dis. 1986; 8(Suppl 5):S634-8.

61. Grayson ML, ed. Kucers' the use of antibiotics: a clinical review of antibacterial, antifungal, antiparasitic, and antiviral drugs. 7th ed. Boca Raton, FL: CRC Press; 2018:.

63. Hampel B, Lode H, Bruckner G et al. Comparative pharmacokinetics of sulbactam/ampicillin and clavulanic acid/amoxycillin in human volunteers. Drugs. 1988; 35(Suppl 7):29-33. http://www.ncbi.nlm.nih.gov/pubmed/3220007?dopt=AbstractPlus

64. Itokazu GS, Danziger LH. Ampicillin-sulbactam and ticarcillin-clavulanic acid: a comparison of their in vitro activity and review of their clinical efficacy. Pharmacotherapy. 1991; 11:382-414. http://www.ncbi.nlm.nih.gov/pubmed/1745624?dopt=AbstractPlus

65. Noguchi JK, Gill MA. Sulbactam: a β-lactamase inhibitor. Clin Pharm. 1988; 7:37-51. http://www.ncbi.nlm.nih.gov/pubmed/3278833?dopt=AbstractPlus

66. Watson ID, Stewart MJ, Platt DJ. Clinical pharmacokinetics of enzyme inhibitors in antimicrobial chemotherapy. Clin Pharmacokinet. 1988; 15:133-64. http://www.ncbi.nlm.nih.gov/pubmed/3052984?dopt=AbstractPlus

67. Ripa S, Ferrante L, Prenna M. Pharmacokinetics of sulbactam/ampicillin in humans after intravenous and intramuscular injection. Chemotherapy. 1990; 36:185-92. http://www.ncbi.nlm.nih.gov/pubmed/2338029?dopt=AbstractPlus

68. Jaresko GS, Barriere SL, Johnson BL Jr. Serum and blister fluid pharmacokinetics and bactericidal activities of ampicillin-sulbactam, cefotetan, cefoxitin, ceftizoxime, and ticarcillin-clavulanate. Antimicrob Agents Chemother. 1992; 36:2233-8. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=245482&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/1444304?dopt=AbstractPlus

69. Aswapokee N, Neu HC. A sulfone β-lactam compound which acts as a β-lactamase inhibitor. J Antibiot. 1978; 31:1238-44. http://www.ncbi.nlm.nih.gov/pubmed/310815?dopt=AbstractPlus

70. Fuchs PC, Stickel S, Anderson PH et al. In vitro inactivation of aminoglycosides by sulbactam, other β-lactams, and sulbactam-β-lactam combinations. Antimicrob Agents Chemother. 1991; 35:182-4. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=244964&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/2014975?dopt=AbstractPlus

71. Nichols RL, Smith JW, Adinolfi MF et al. Inhibition of β-lactamase-induced resistance in soft-tissue infections. Arch Surg. 1985; 120:36-42. http://www.ncbi.nlm.nih.gov/pubmed/2981523?dopt=AbstractPlus

72. Kerins DM. Ampicillin/sulbactam—a combination of an old and a new agent in the treatment of infection. Am J Med Sci. 1991; 301:406-11. http://www.ncbi.nlm.nih.gov/pubmed/2039029?dopt=AbstractPlus

73. Schwiersch U, Lang N, Wildfeuer DA. Concentration of sulbactam and ampicillin in serum and the myometrium. Drugs. 1986; 31(Suppl 2):26-8. http://www.ncbi.nlm.nih.gov/pubmed/3013570?dopt=AbstractPlus

74. Gunning J. A comparison of parenteral sulbactam/ampicillin versus clindamycin/gentamicin in the treatment of pelvic inflammatory disease. Drugs. 1986; 31(Suppl 2):14-7. http://www.ncbi.nlm.nih.gov/pubmed/3013567?dopt=AbstractPlus

75. Crombleholme W, Landers D, Ohm-Smith M et al. Sulbactam/ampicillin versus metronidazole/gentamicin in the treatment of severe pelvic infections. Drugs. 1986; 31(Suppl 2):11-3. http://www.ncbi.nlm.nih.gov/pubmed/3013566?dopt=AbstractPlus

76. Bruhat MA, Pouly JL, Le Boedec G et al. Treatment of acute salpingitis with sulbactam/ampicillin: comparison with cefoxitin. Drugs. 1986; 31(Suppl 2):7-10. http://www.ncbi.nlm.nih.gov/pubmed/3013571?dopt=AbstractPlus

77. Oviasu VO, Obasohan AO. Effectiveness of sulbactam/ampicillin in the treatment of lobar pneumonia. Curr Ther Res. 1987; 41:99-104.

78. Dutse AI, Fakunle YM, Oyeyinka GO et al. Sulbactam/ampicillin in epidemic meningococcal meningitis in northern Nigeria. Curr Ther Res. 1987; 41:128-34.

80. Rotowa NA, Asuzu MC, Adelushi B et al. The efficacy of sulbactam/ampicillin in the treatment of uncomplicated penicillin-resistant gonococcal infection. Curr Ther Res. 1987; 42:351-6.

81. Valcke Y, Van der Straeten M. A noncomparative study of the safety and efficacy of parenteral sulbactam/ampicillin followed by oral sultamicillin for the treatment of lower respiratory tract infections. Curr Ther Res. 1989; 45:43-7.

82. Ito MK, Gill MA, Yellin AE et al. The cost effectiveness of sulbactam-ampicillin versus moxalactam in the management of acute cholecystitis. Curr Ther Res. 1989; 46:747-54.

83. Cunha BA. Treatment of pelvic inflammatory disease. Clin Pharm. 1990; 9:275-85. http://www.ncbi.nlm.nih.gov/pubmed/2184973?dopt=AbstractPlus

84. Morales JJ, de la Cabada Cortesé FJ, Villanueva JA et al. Sulbactam plus ampicillin in the treatment of lower respiratory tract infections. Curr Ther Res. 1990; 48:548-54.

85. Zenon GJ, Cadle RM, Hamill RJ. Ampicillin-sulbactam therapy for multiple pyogenic hepatic abscesses. Clin Pharm. 1990; 9:939-47. http://www.ncbi.nlm.nih.gov/pubmed/2292177?dopt=AbstractPlus

86. Andreoni M, Raillard P, Concia E et al. Sulbactam/ampicillin in the treatment of skin and soft-tissue infections due to methicillin-resistant staphylococci. Curr Ther Res. 1991; 50:386-95.

87. Dajani AS. Sulbactam/ampicillin in paediatric infections. Drugs. 1988; 35(Suppl 7):35-8. http://www.ncbi.nlm.nih.gov/pubmed/3065053?dopt=AbstractPlus

88. Gunëren MF. Clinical experience with intramuscular sulbactam/ampicillin in the outpatient treatment of various infections: a multicentre trial. Drugs. 1988; 35(Suppl 7):57-68.

89. Castellano MA. Sulbactam/ampicillin in the treatment of lower respiratory infections. Drugs. 1988; 35(Suppl 7):53-6. http://www.ncbi.nlm.nih.gov/pubmed/3065054?dopt=AbstractPlus

90. Löffler L, Bauernfeind A, Keyl W. Sulbactam/ampicillin versus cefotaxime as initial therapy in serious soft tissue, joint and bone infections. Drugs. 1988; 35(Suppl 7):46-52. http://www.ncbi.nlm.nih.gov/pubmed/3265378?dopt=AbstractPlus

91. Hemsell DL, Heard MC, Hemsell PG et al. Sulbactam/ampicillin versus cefoxitin for uncomplicated and complicated acute pelvic inflammatory disease. Drugs. 1988; 35(Suppl 7):39-42. http://www.ncbi.nlm.nih.gov/pubmed/3220008?dopt=AbstractPlus

92. Roerig. Unasyn IM/IV (ampicillin sodium/sulbactam sodium) formulary review. New York, NY; 1987 Sep.

93. Urban C, Go E, Mariano N et al. Effect of sulbactam on infections caused by imipenem-resistant Acinetobacter calcoaceticus biotype anitratus. J Infect Dis. 1993; 167:448-51. http://www.ncbi.nlm.nih.gov/pubmed/8421178?dopt=AbstractPlus

94. Kim JH, Choi KH, Kim YT et al. Treatment of infections due to multiresistant Neisseria gonorrhoeae with sulbactam/ampicillin. Rev Infect Dis. 1986; 8(Suppl 5):S599-602. http://www.ncbi.nlm.nih.gov/pubmed/3026010?dopt=AbstractPlus

95. Houang ET, Reardon P. Single-dose intramuscular sulbactam and ampicillin in treating acute uncomplicated gonorrhoea. Genitourin Med. 1985; 61:209-13. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1011806&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/2989156?dopt=AbstractPlus

96. . Antimicrobial prophylaxis for surgery. Med Lett Drugs Ther. 2016; 58:63-8. http://www.ncbi.nlm.nih.gov/pubmed/27192618?dopt=AbstractPlus

97. Bratzler DW, Dellinger EP, Olsen KM et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery. Am J Health Syst Pharm. 2013; 70:195-283. http://www.ncbi.nlm.nih.gov/pubmed/23327981?dopt=AbstractPlus

98. Edwards GF, Lindsay G, Taylor EW. A bacteriologic assessment of ampicillin with sulbactam as antibiotic prophylaxis in patients undergoing biliary tract operations. The West of Scotland Surgical Infection Study Group. J Hosp Infect. 1990; 16:249-55. http://www.ncbi.nlm.nih.gov/pubmed/1979575?dopt=AbstractPlus

99. Wittmann DH, Koltowski O, Oleszkiewicz J et al. Infectious complications after 809 biliary tract operations and results of a prospective randomized single-blind study comparing cefoxitin versus ampicillin plus an inhibitor of β-lactamases. Infection. 1990; 18:41-7. http://www.ncbi.nlm.nih.gov/pubmed/2179137?dopt=AbstractPlus

101. Reviewers’ comments (personal observations).

102. Pfizer Inc, New York, NY: Personal communication.

108. Foulds G, Miller RD, Knirsch AK et al. Sulbactam kinetics and excretion into breast milk in postpartum women. Clin Pharmacol Ther. 1985; 38:692-6. http://www.ncbi.nlm.nih.gov/pubmed/2998677?dopt=AbstractPlus

109. Mylan. Methotrexate injection prescribing information. Rockford, IL; 2016 Jul.

110. Mushinsky RF, Reynolds ML, Nicholson CA et al. Stability of sulbactam/ampicillin in diluents for parenteral administration. Rev Infect Dis. 1986; 8(Suppl 5):S523-7. http://www.ncbi.nlm.nih.gov/pubmed/3026000?dopt=AbstractPlus

111. O’Brien MA, Mason NA. Systemic absorption of intraperitoneal antimicrobials in continuous ambulatory peritoneal dialysis. Clin Pharm. 1992; 11:246-54. http://www.ncbi.nlm.nih.gov/pubmed/1611814?dopt=AbstractPlus

112. Wald E, Reilly JS, Bluestone CD et al. Sulbactam/ampicillin in the treatment of acute epiglottitis in children. Rev Infect Dis. 1986; 8(Suppl 5):S617-9. http://www.ncbi.nlm.nih.gov/pubmed/3026014?dopt=AbstractPlus

113. Syriopoulou V, Bitsi M, Theodoridis C et al. Clinical efficacy of sulbactam/ampicillin in pediatric infections caused by ampicillin-resistant or penicillin-resistant organisms. Rev Infect Dis. 1986; 8(Suppl 5):S630-3. http://www.ncbi.nlm.nih.gov/pubmed/3026016?dopt=AbstractPlus

114. Aronoff SC, Scoles PV, Makley JT et al. Efficacy and safety of sequential treatment of parenteral sulbactam/ampicillin and oral sultamicillin for skeletal infections in children. Rev Infect Dis. 1986; 8(Suppl 5):S639-42. http://www.ncbi.nlm.nih.gov/pubmed/3026018?dopt=AbstractPlus

115. Chin NX, McElrath MJ, Neu HC. Beta-lactamase inhibition by acetylmethylene penicillanic acid compared to that of clavulanate and sulbactam. Chemotherapy. 1988; 34:318-25. http://www.ncbi.nlm.nih.gov/pubmed/2850139?dopt=AbstractPlus

116. Lorian V, ed. Antibiotics in laboratory medicine. Baltimore: Williams & Wilkins; 1980:298-341, 418-73, 607-722.

117. Antonio-Velmonte M, Alora BD, Billote J et al. Comparative in vitro activity of ampicillin and sulbactam/ampicillin combination. Curr Ther Res. 1988; 43:786-93.

118. Williams JD. Importance of β-lactamases and clinical implications of their inhibitors. Drugs. 1988; 35(Suppl 7):3-11. http://www.ncbi.nlm.nih.gov/pubmed/3065052?dopt=AbstractPlus

119. Jones RN. In vitro evaluations of aminopenicillin/β-lactamase inhibitor combinations. Drugs. 1988; 35(Suppl 7):17-26. http://www.ncbi.nlm.nih.gov/pubmed/3265377?dopt=AbstractPlus

120. Bourgault AM, Lamothe F, Hoban DJ et al. Survey ofBacteroides fragilisgroup susceptibility patterns of Canada. Antimicrob Agents Chemother. 1992; 36:343-7. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=188439&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/1605600?dopt=AbstractPlus

121. Sookpranee T, Sookpranee M, Mellencamp MA et al. Pseudomonas pseudomallei, a common pathogen in Thailand that is resistant to the bactericidal effects of many antibiotics. Antimicrob Agents Chemother. 1991; 35:484-9. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=245036&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/2039198?dopt=AbstractPlus

122. Wexler HM, Molitoris E, Finegold SM. Effect of β-lactamase inhibitors on the activities of various β-lactam agents against anaerobic bacteria. Antimicrob Agents Chemother. 1991; 1219-24.

123. Jorgensen JH, Doern GV, Maher LA et al. Antimicrobial resistance among respiratory isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae in the United States. Antimicrob Agents Chemother. 1990; 34:2075-80. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=172002&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/2127342?dopt=AbstractPlus

124. Van der Auwera P, Scorneaux B. In vitro susceptibilities of Campylobacter jejuni to 27 antimicrobial agents and various combinations of β-lactams with clavulanic acid or sulbactam. Antimicrob Agents Chemother. 1985; 28:37-40. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=176305&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/2994557?dopt=AbstractPlus

125. Barry AL, Jones RN. In vitro activities of ampicillin-sulbactam and cefoperazone-sulbactam against oxacillin-susceptible and oxacillin-resistant staphylococci. Antimicrob Agents Chemother. 1990; 34:1830-2. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=171941&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/2285302?dopt=AbstractPlus

126. Pelaez MT. Resistance of anaerobic bacteria to antimicrobial agents. Rev Infect Dis. 1991; 13:183.

127. Azimi PH, Dunphy MG. Susceptibility of Haemophilus influenzae type b to ampicillin-sulbactam. Antimicrob Agents Chemother. 1989; 33:1620-1. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=172715&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/2817860?dopt=AbstractPlus

128. Jacoby GA, Sutton L. Pseudomonas cepacia susceptibility to sulbactam. Antimicrob Agents Chemother. 1989; 33:583-4. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=172485&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/2729951?dopt=AbstractPlus

129. Farmer TH, Reading C. The effects of clavulanic acid and sulbactam on β-lactamase biosynthesis. J Antimicrob Chemother. 1988; 22:105-11. http://www.ncbi.nlm.nih.gov/pubmed/3263350?dopt=AbstractPlus

130. Jones RN, Barry AL. In-vitro activity of ampicillin/sulbactam against cefoxitin-resistant anaerobic bacteria. J Antimicrob Chemother. 1988; 21:135-8. http://www.ncbi.nlm.nih.gov/pubmed/3356620?dopt=AbstractPlus

131. Kazmierczak A, Duez JM, Pechinot A et al. In vitro bactericidal activity of sulbactam plus ampicillin against methicillin-resistant Staphylococcus aureus. Rev Infect Dis. 1986; 8(Suppl 5):S549-54. http://www.ncbi.nlm.nih.gov/pubmed/3026003?dopt=AbstractPlus

132. Retsema JA, English AR, Girard A et al. Sulbactam/ampicillin: in vitro spectrum, potency, and activity in models of acute infection. Rev Infect Dis. 1986; 8(Suppl 5):S528-34. http://www.ncbi.nlm.nih.gov/pubmed/3026001?dopt=AbstractPlus

133. Bauernfeind A. Classification of β-lactamases. Rev Infect Dis. 1986; 8(Suppl 5):S470-80.

134. Labia R, Morand A, Lelievre V et al. Sulbactam: biochemical factors involved in its synergy with ampicillin. Rev Infect Dis. 1986; 8(Suppl 5):S496-502. http://www.ncbi.nlm.nih.gov/pubmed/3025996?dopt=AbstractPlus

135. Sanders CC, Sanders WE Jr. Type I β-lactamases of gram-negative bacteria: interactions with β-lactam antibiotics. J Infect Dis. 1986; 154:792-800. http://www.ncbi.nlm.nih.gov/pubmed/3490520?dopt=AbstractPlus

136. Wexler HM, Harris B, Carter WT et al. In vitro efficacy of sulbactam combined with ampicillin against anaerobic bacteria. Antimicrob Agents Chemother. 1985; 27:876-8. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=180171&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/2990330?dopt=AbstractPlus

137. Retsema JA, English AR, Girard AE. CP-45,899 in combination with penicillin or ampicillin against penicillin-resistant Staphylococcus, Haemophilus influenzae, and Bacteroides. Antimicrob Agents Chemother. 1980; 17:615-22. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=283841&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/6249192?dopt=AbstractPlus

138. Voelker MS, Nightingale CH, Quintiliani R et al. Sultamicillin(R)use in otitis media: penetration of sulbactam, a beta-lactamase inhibitor, and ampicillin into middle-ear fluid. Curr Ther Res. 1985; 38:738-45.

139. Phan M, Van der Auwera P, Andry G et al. Antimicrobial prophylaxis for major head and neck surgery in cancer patients: sulbactam-ampicillin versus clindamycin-amikacin. Antimicrob Agents Chemother. 1992; 36:2014-9. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=192428&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/1416895?dopt=AbstractPlus

140. Davies BI, Maesen FPV, van Noord JA. Clinical, bacteriological and pharmacokinetic results from an open trial of sultamicillin in patients with acute exacerbations of chronic bronchitis. J Antimicrob Chemother. 1984; 13:161-70. http://www.ncbi.nlm.nih.gov/pubmed/6323377?dopt=AbstractPlus

141. Pefanis A, Thauvin-Eliopoulos C, Eliopoulos GM et al. Activity of ampicillin-sulbactam and oxacillin in experimental endocarditis caused by β-lactamase-hyperproducing Staphylococcus aureus. Antimicrob Agents Chemother. 1993; 37:507-11. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=187700&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/8460919?dopt=AbstractPlus

142. Jones S, Yu VL, Johnson JT et al. Pharmacokinetic and therapeutic trial of sultamicillin in acute sinusitis. Antimicrob Agents Chemother. 1985; 28:832-3. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=180339&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/3002247?dopt=AbstractPlus

143. Acar JF, Gutmann L, Kitzis MD. β-Lactamases in clinical isolates: spectrum implications of sulbactam/ampicillin. Drugs. 1988; 35(Suppl 7):12-6. http://www.ncbi.nlm.nih.gov/pubmed/3065051?dopt=AbstractPlus

144. De Simone C, Chiodo F, Delia S et al. Clinical results of a multicenter study with sulbactam/ampicillin for the treatment of patients with lower respiratory and urinary tract infections. J Chemother. 1991; 3:321-7. http://www.ncbi.nlm.nih.gov/pubmed/1809811?dopt=AbstractPlus

145. Weber RS, Raad I, Frankenthaler R et al. Ampicillin-sulbactam vs clindamycin in head and neck oncologic surgery. Arch Otolaryngol Head Neck Surg. 1992; 118:1159-63. http://www.ncbi.nlm.nih.gov/pubmed/1418893?dopt=AbstractPlus

146. Martens MG, Faro S. Beta-lactam antibiotics and Chlamydia trachomatis. 1988; 5:113-20.

147. Toomey KE, Barnes RC. Treatment of Chlamydia trachomatis genital infection. Clin Infect Dis. 1990; 12(Suppl 6):S645-55.

148. Segreti J, Kapell KS, Trenholme GM. In vitro activity of β-lactam drugs and sulbactam against Chlamydia trachomatis. Diagn Microbiol Infect Dis. 1992; 15:371-3. http://www.ncbi.nlm.nih.gov/pubmed/1611854?dopt=AbstractPlus

149. Spera RV, Farber BF. Multiply-resistantEnterococcus faecium: the nosocomial pathogen of the 1990s. JAMA. 1993; 268:2563-4.

150. Klare I, Rodloff AC, Wagner J et al. Overproduction of a penicillin-binding protein is not the only mechanism of penicillin resistance inEnterococcus faecium. Antimicrob Agents Chemother. 1992; 36:783-7. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=189409&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/1503440?dopt=AbstractPlus

151. Handwerger S, Perlman DC, Altarae D et al. Concomitant high-level vancomycin and penicillin resistance in clinical isolates of Enterococci. Clin Infect Dis. 1992; 14:655-61.

265. Centers for Disease Control. Sexually transmitted diseases treatment guidelines 1989. MMWR Morb Mortal Wkly Rep. 1989; 38(Suppl 8S):1-43S. http://www.ncbi.nlm.nih.gov/pubmed/2491906?dopt=AbstractPlus

282. Serra P, Brandimarte C, Martino P et al. Synergistic treatment of enterococcal endocarditis: in vitro and in vivo studies. Arch Intern Med. 1977; 137:1562-7. http://www.ncbi.nlm.nih.gov/pubmed/921443?dopt=AbstractPlus

300. ASHP Injectable Drug Information. Ampicillin (updated May 1, 2020). Bethesda, MD: American Society of Health-System Pharmacist.

301. ASHP Injectable Drug Information. Ampicillin Sodium-Sulbactam Sodium (updated Apr 30, 2021). Bethesda, MD: American Society of Health-System Pharmacist.

302. McDonald LC, Gerding DN, Johnson S et al. Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 2018; 66:987-994. http://www.ncbi.nlm.nih.gov/pubmed/29562266?dopt=AbstractPlus

303. US Food and Drug Administration. FDA-recognized antimicrobial susceptibility test interpretive criteria. From FDA website. Accessed 2021 Jul 8. https://www.fda.gov/STIC

304. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing. 31st edition. CLSI supplement M100. Wayne, PA; Mar 2021. http://em100.edaptivedocs.net/dashboard.aspx

305. Metlay JP, Waterer GW, Long AC et al. Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019; 200:e45-e67. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=PMC6812437&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/31573350?dopt=AbstractPlus

344. Workowski KA, Bachmann LH, Chan PA et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep. 2021; 70:1-187. http://www.ncbi.nlm.nih.gov/pubmed/34292926?dopt=AbstractPlus

450. Baddour LM, Wilson WR, Bayer AS et al. Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Scientific Statement for Healthcare Professionals From the American Heart Association. Circulation. 2015; 132:1435-86. http://www.ncbi.nlm.nih.gov/pubmed/26373316?dopt=AbstractPlus

452. Baltimore RS, Gewitz M, Baddour LM et al. Infective Endocarditis in Childhood: 2015 Update: A Scientific Statement From the American Heart Association. Circulation. 2015; 132:1487-515. http://www.ncbi.nlm.nih.gov/pubmed/26373317?dopt=AbstractPlus

Medical Disclaimer